Phase 2b dose-ranging study of VX-765 in treatment-resistant partial epilepsy
Epilepsy
Enrolment: 55 · Results not recorded
Loading the evidence…
Drug · Caspase-1 inhibitor (INHIBITOR, direct interaction); prodrug
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Epilepsy
Enrolment: 55 · Results not recorded
COVID-19
Enrolment: 40 · Results not recorded
Psoriasis
Enrolment: 64 · Results not recorded
Partial Epilepsy
Enrolment: 60 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Contusive thoracic (T9) spinal cord injury using an Infinite Horizon impactor, 1.3 mm rod, 50 Kdynes force, 0 sec dwell time
VX-765 inhibited activation of caspase-1 and caspase-3 in injured spinal cords and produced 1,137 upregulated and 1,762 downregulated differentially expressed genes, with downregulated pathways including focal adhesion, cytokine-cytokine receptor interaction, leukocyte transendothelial migration, E…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.
Model: Weight-drop closed-skull contusion; a 200 g flat-ended steel weight dropped from 5 cm onto the left lateral skull producing moderate contusion of the left parietal cortex. In vitro: mechanical scratch, equiaxial stretch (12% strain, 1.0 Hz, 4 h) and LPS plus 5 mM ATP
Caspase-1 ablation reduced neurological deficits, cortical apoptosis, serum LDH, IFN-gamma and NLRP3 pathway signalling while raising TGF-beta and IL-10, and lowered caspase-1 activity, caspase-11 and GSDMD; in vitro caspase-1 siRNA and VX-765 similarly reduced neuronal apoptosis, LDH release and I…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.